Biliary Tract Cancer After Surgery: When Can a Second Opinion Help?

Published: 2026-09-27 · Sources checked: 2026-09-27 · Medical review: pending professional review.

Direct answer: A decision about chemotherapy after surgery cannot rest on the phrase “the tumor was removed.” In the Japanese randomized phase III ASCOT trial, five-year overall survival was 64% in the adjuvant S-1 group and 52% in the observation group. Those are outcomes across groups of trial participants. They cannot predict one person's result or establish that S-1 is appropriate for everyone with biliary tract cancer.

Why this decision can feel unsettled

Families may hear that surgery removed all visible disease and that surveillance is reasonable. They may also hear that microscopic disease could remain and that postoperative treatment deserves consideration. Both discussions depend on details that are easy to lose in a short clinic visit: the exact site and type of tumor, what the pathologist found, the surgical margin, lymph nodes, recovery from surgery, and the patient's priorities.

The recently published five-year update is useful because it adds longer follow-up to an existing phase III trial. It is a clinical trial result, not an announcement of a new drug approval. The ASCOT participants had resected biliary tract cancer and met defined entry criteria. The original trial included intrahepatic and extrahepatic bile duct cancer, gallbladder cancer, and ampullary cancer after R0 or R1 surgery. It did not study patients with an unresectable tumor or an established recurrence.

What exactly did ASCOT report?

ASCOT compared postoperative S-1, an oral fluoropyrimidine chemotherapy, with observation. At the final five-year analysis, overall survival favored the S-1 group: 64% versus 52%, with a hazard ratio of 0.72. The paper also reported a meaningful relapse-free survival benefit. The population, treatment schedule, and follow-up protocol matter when interpreting those figures. An individual patient's expected benefit may be smaller, larger, or uncertain.

A second opinion should therefore start with applicability rather than the headline number. What operation was performed? Was the resection R0 or R1? Were lymph nodes involved? Is the pathology diagnosis secure? How well has the patient recovered? Could organ function, nutrition, other illnesses, or treatment preferences alter the balance between possible benefit and treatment burden?

What a Japanese specialist may reassess

  1. Diagnosis and stage. Review the operative and pathology reports, tumor location, grade, margins, nodes, and the most recent imaging. Discrepant reports may call for pathology or imaging review.
  2. Fit with the evidence. Compare the patient's case with the ASCOT trial population and with the treatment options available where the patient lives. Practice guidelines and drug availability vary by country.
  3. Readiness for further treatment. Consider postoperative complications, performance status, nutrition, kidney and liver function, and the patient's tolerance for additional therapy.
  4. A workable follow-up plan. Clarify what surveillance would involve, how adverse effects would be monitored if treatment starts, and which findings would prompt reassessment.

Who may find a second opinion useful?

It can be useful when a patient has completed surgery but has not yet settled on an adjuvant plan, when hospitals give different recommendations, when pathology or imaging findings are uncertain, or when recovery and other medical conditions complicate treatment. Confirmation that the current plan is sound is also a valuable outcome.

Urgent problems need local care first. New or worsening jaundice, fever or suspected infection, uncontrolled pain, and other rapidly changing symptoms should be assessed promptly by the treating team. A remote review should not delay urgent treatment.

What to prepare, and what happens next

For a structured review, gather the operative report, complete pathology report, original imaging files and reports, discharge summary, recent laboratory results, current medication list, and a dated treatment timeline. Write three to five focused questions. For example: “How was the margin classified?”, “How closely does this case match ASCOT?”, and “What would change the proposed plan?”

After receiving written recommendations, discuss them with the local surgeon and medical oncologist. A specialist might confirm the existing plan, recommend additional review, or suggest a different sequence. A second opinion is a decision aid; it does not guarantee a change in treatment and does not automatically require travel to Japan.

Frequently asked questions

Does the 12-point difference mean I personally gain 12%?

No. The figures describe groups in a randomized trial. Individual risk and benefit depend on pathology, health status, and later care.

If the surgical margin is clear, can treatment be skipped?

A clear margin is important, but it is one part of risk assessment. The full pathology and clinical picture still need review.

Will a Japanese specialist recommend an experimental drug?

The first task is to assess diagnosis, stage, and established evidence. Approved treatments, clinical trials, and individual-use approaches have different requirements and must be discussed separately.

Must a patient travel to Japan for a second opinion?

No. A written remote opinion may help inform a discussion with the treating team at home. Travel is relevant only if a later investigation or treatment requires it.

Primary sources

Evidence checked: September 27, 2026. This article provides medical education and cannot establish a diagnosis, prescription, trial eligibility, or an individual prognosis.

Japan Expert Second Opinion: If a postoperative plan remains unclear, a structured written review can help frame the questions to take back to your treating team. Any transfer of medical information should use a private, secure process rather than public comments.